IMUX.US Immunic Inc

Healthcare Biotechnology USA Stocks
7.52 USD
Close of Nov 15, 2026
5.06 17.43
Market cap
USD 103M
P/E
-
P/B
0.81x
ROE
-139.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IMUX.US undervalued?

Graham number

The Graham number of Immunic Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immunic Inc fundamental analysis

No fundamental analysis for Immunic Inc yet.

Immunic Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immunic Inc

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical …

Full company profile